title: Challenges and opportunities for non-antibody scaffold drugs.
abstract: The first candidates from the promising class of small non-antibody protein scaffolds are now moving into clinical development and practice. Challenges remain, and scaffolds will need to be further tailored toward applications where they provide real advantages over established therapeutics to succeed in a rapidly evolving drug development landscape.
authors.affiliation: Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The University of New South Wales, Faculty of Medicine, St Vincent's Clinical School, Darlinghurst, Sydney, NSW 2010, Australia.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Vazquez-Lombardi
authors.affiliation: Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The University of New South Wales, Faculty of Medicine, St Vincent's Clinical School, Darlinghurst, Sydney, NSW 2010, Australia.
authors.forename: Tri Giang
authors.initials: TG
authors.lastname: Phan
authors.affiliation: University of San Diego, School of Business Administration, 5998 Alcala Park, San Diego, CA 92110, USA.
authors.forename: Carsten
authors.initials: C
authors.lastname: Zimmermann
authors.affiliation: MedImmune Ltd., Granta Park, Cambridge CB21 6GH, UK.
authors.forename: David
authors.initials: D
authors.lastname: Lowe
authors.affiliation: MedImmune Ltd., Granta Park, Cambridge CB21 6GH, UK; Trinity Hall, University of Cambridge, Trinity Lane CB2 1TJ, UK. Electronic address: jermutusl@medimmune.com.
authors.forename: Lutz
authors.initials: L
authors.lastname: Jermutus
authors.affiliation: Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The University of New South Wales, Faculty of Medicine, St Vincent's Clinical School, Darlinghurst, Sydney, NSW 2010, Australia. Electronic address: d.christ@garvan.org.au.
authors.forename: Daniel
authors.initials: D
authors.lastname: Christ
mesh_terms: D000818:Animals; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D011506:Proteins / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D011506:Proteins